One Stock Superinvestors Are Selling

As part of the weekly research here at The Acquirer’s Multiple we’re always interested in superinvestors who hold the same stocks that appear in our Acquirer’s Multiple Stock Screeners, based on their latest 13F’s. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks.

While doing this research we’ve also uncovered a number of stocks that superinvestors have sold, or reduced in their portfolios, according to their latest 13f’s. So we’re now providing a new weekly feature article called ‘One Stock Superinvestors Are Selling‘. This week we’ll take a look at:

Bristol-Myers Squibb Co (NYSE: BMY)

Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

A quick look at the price chart below for Bristol-Myers Squibb shows us that the stock is up 28% in the past twelve months.

(Source: Morningstar)

Superinvestors who sold, or reduced Bristol-Myers Squibb stock to their portfolios include:

(Superinvestor – remaining shares)

Jim Simons – 43,497,131 shares

Cliff Asness – 3,408,283 shares

Rich Pzena – 1,462,708 shares

Khan Brothers – 1,015,804 shares

Mario Gabelli – 224,577 shares

Ken Fisher – 172,283 shares

Jeremy Grantham – 77,291 shares

Lee Ainslie – 65,373 shares

Murray Stahl – 51,034 shares